Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
Public ClinicalTrials.gov record NCT01939496. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Blood Pressure Reduction With Ambulatory Blood Pressure Monitoring (ABPM), Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Hypertension and Type 2 Diabetes Mellitus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the effect of canagliflozin (JNJ-28431754) on blood pressure reduction, compared to placebo, in patients with hypertension and type 2 diabetes mellitus and who are on stable doses of anti-hyperglycemic and anti-hypertensive agents. Overall safety and tolerability of canagliflozin will be assessed.
Study identification
- NCT ID
- NCT01939496
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 171 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2013 (Type not available)
- Primary completion
- Apr 2015 (Actual)
- Completion
- Apr 2015 (Actual)
- Last update posted
- Mar 3, 2017
2013 – 2015
United States locations
- U.S. sites
- 54
- U.S. states
- 24
- U.S. cities
- 54
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Gulf Shores | Alabama | — | — |
| Not listed | Avondale | Arizona | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Glendale | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Newport Beach | California | — | — |
| Not listed | Pismo Beach | California | — | — |
| Not listed | Rancho Cucamonga | California | — | — |
| Not listed | Roseville | California | — | — |
| Not listed | Sacramento | California | — | — |
| Not listed | Spring Valley | California | — | — |
| Not listed | Tustin | California | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Brandon | Florida | — | — |
| Not listed | Doral | Florida | — | — |
| Not listed | Fort Lauderdale | Florida | — | — |
| Not listed | Lake Worth | Florida | — | — |
| Not listed | Lauderdale Lakes | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Miami Lakes | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Pembroke Pines | Florida | — | — |
| Not listed | Port Orange | Florida | — | — |
| Not listed | West Palm Beach | Florida | — | — |
| Not listed | Perry | Georgia | — | — |
| Not listed | Rincon | Georgia | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Topeka | Kansas | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Mandeville | Louisiana | — | — |
| Not listed | Marrero | Louisiana | — | — |
| Not listed | Metairie | Louisiana | — | — |
| Not listed | Auburn | Maine | — | — |
| Not listed | Elkridge | Maryland | — | — |
| Not listed | Dearborn | Michigan | — | — |
| Not listed | Kalamazoo | Michigan | — | — |
| Not listed | Jackson | Mississippi | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Morganville | New Jersey | — | — |
| Not listed | Whiting | New Jersey | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Altoona | Pennsylvania | — | — |
| Not listed | Jenkintown | Pennsylvania | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Plano | Texas | — | — |
| Not listed | Sugar Land | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Renton | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01939496, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 3, 2017 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01939496 live on ClinicalTrials.gov.